Net profit of Rs 141.7 crore was recorded by drug major Wockhardt had for the quarter ended December.

Owing to mark to market losses and financial commotion in global markets the company had a net loss of Rs 181.2 crore for the corresponding quarter for the year ago period.

When compared to last year's income Rs 889.3 crore in the same quarter, this year the income from operations rose 6.9 % to Rs 950.8 crore

Income from operations grew 6.9 per cent in the quarter to Rs 950.8 crore, from Rs 889.3 crore in the same quarter of last year.

"Our operations remain strong and have consistently shown growth in Ebitda (earnings before interest, taxes, depreciation and amortization) and Ebitda margins during the current year," said Habil Khorakiwala, chairman.

According to a press release, for the quarter Ebitda increased by 82 % whereas the Ebitda margin was 25.6.

The India centric business for the drug company showed a growth of18 % during the quarter and it was marked by launch of two new products by the company.

In the domestic market presently, eight brands feature among the top 300. Also for the company, exports increased by 30 %.

On the Bombay Stock Exchange, stocks of Wockhardt ascended by 4.99 per cent on Thursday morning and are currently trading at Rs 398.40 per share, up by 18.55 points.

A growth of 87% was recorded for Wockhardt USA for the quarter; also eight new products were launched last year. This takes the total number of products in the market sold by it to 123.